
A peek inside some leading research labs shows how scientists-turned-detectives are painstakingly decoding what causes autoimmune diseases and how to stop the immune system from attacking you instead of protecting you.
It’s a huge challenge. By the National Institutes of Health’s newest count there are about 140 autoimmune diseases affecting tens of millions of people.
Unraveling them requires patience, persistence — and sophisticated technology to even see the suspects. Researchers use laser-powered machinery and brightly colored fluorescent dyes to tell rogue cells from normal ones.
Take Type 1 diabetes, caused when cells in the pancreas that produce insulin are gradually killed off by rogue T cells. In a biomedical engineering lab at Johns Hopkins University, researchers examine mouse pancreas cells on a computer screen. Red marks the killer cells. In yellow are “peacemaker” cells that are supposed to tamp down autoimmune reactions – but they’re outnumbered.
Another type of immune cell, B cells, drive autoimmune diseases by producing antibodies that mistake healthy tissue for foreign invaders. At NIH, Dr. Iago Pinal-Fernandez studies myositis, a poorly understood group of muscle-weakening diseases. His research shows rogue antibodies don’t just damage muscles by latching onto their surface. They can sneak inside muscle cells and disrupt their normal functions in ways that help explain varying symptoms.
“When I started, nothing was known about the type of autoimmune disease we study. Now finally we’re able to tell patients, ’You have this disease and this is the mechanism of disease,” he said.
In another NIH lab, Dr. Mariana Kaplan’s team is hunting the root causes of lupus and other autoimmune diseases — what makes the immune system run amok in the first place — and why they so often strike women.
Today's drugs tamp down symptoms but don't correct the problem. Now in early-phase clinical trials are treatments that instead aim to fix dysfunctional immune pathways.
At Hopkins, scientists are working on next-generation versions, not yet ready to try in people. In one lab, they're developing nanoparticle-based treatment to dial down pancreas-killing cells in Type 1 diabetes and ramp up “peacemaker” cells.
And in another Hopkins lab, researchers are developing what they hope will become more precise treatments for rheumatoid arthritis, lupus and other antibody-driven illnesses – drugs that search out and destroy “bad” B cells.
—-
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
This is a documentary photo story curated by AP photo editors.
LATEST POSTS
- 1
I spent the last year transforming my life. Becoming a Rockette for a day made me confront a fear I couldn't shake. - 2
Israel kidnaps PIJ terrorist in covert op. in Hamas-controlled Gaza in pursuit of Ran Gvili - 3
Tech Patterns: Contraptions That Will Shape What's in store - 4
'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war - 5
The cave was pitch black – so to create this magical underwater shot, the photographer had to use all his camera expertise...
Minneapolis ICE shooting: Woman dies after federal agent opens fire on her vehicle amid immigration crackdown
'Peaky Blinders: The Immortal Man' teaser trailer reveals Cillian Murphy's Tommy Shelby back in action
College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
Scientists may be overestimating the amount of microplastics in the environment – and the culprit is lab gloves
Hostile to Maturing Skincare Items to Rejuvenate Your Skin
Car Investigation: A Survey of \Past the Outside\ Car
A Republican elected governor in California? It's not as far-fetched as it sounds.
Palestinians forced from West Bank refugee camps left in limbo as Israeli demolitions go on
NASA set for first crewed moon return in over half a century











